Rubius Therapeutics Inc Watch

from 8-K 6 pages Agreement for Termination of Lease

from 8-K 30 pages Purchase and Sale Agreement by and Between Rubius Therapeutics, Inc. (“Seller”) and DIV Acquisition V, LLC

from 10-K 2 pages ​ Rubius Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 8-K 20 pages Employment Agreement

from 8-K 19 pages Employment Agreement

from 10-Q 10 pages June 29, 2020 ​ Andrew Oh [***] [***] ​ Re:transitional Services and Separation Agreement ​ Dear Andrew

from 10-Q 20 pages Employment Agreement

from 10-Q 20 pages Employment Agreement

from 10-K 20 pages Employment Agreement

from 10-Q 10 pages May 14, 2019 Torben Straight Nissen, PH.D. [* * *] [* * *] Re: Resignation and Post-Employment Senior Advisory Role Dear Torben

from 10-K/A 4 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed

from 10-K/A 16 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Lease

from 10-K 4 pages This Second Amendment, Effective as of July 25, 2018 (The “Second Amendment Effective Date”), Amends the Exclusive Patent License Agreement Dated January 28, 2016, and First Amendment Dated December 12, 2017 (The “License”), Between the Whitehead Institute for Biomedical Research (“Whitehead”) and Rubius Therapeutics, Inc. (“Company”). Whereas, Whitehead and Company Wish to Modify Appendix a of the License; Whereas, Whitehead Is Owner of Certain Second Amendment Patent Rights, as Later Defined Herein, Relating to [***], “[***]”, by [***]; Whereas, Whitehead Desires to Have the Patent Rights Developed and Commercialized to Benefit the Public, and Whitehead Is Willing to Grant a License Thereunder; Whereas, Company Desires to Add Such Second Amendment Patent Rights to the License. Now, Therefore, Whitehead and Company Hereby Agree as Follows: Capitalized Terms Used Herein and Not Defined Herein Shall Have the Respective Meanings Ascribed to Such Terms in the License. 1. the Following (Hereinafter the “Second Amendment Patent Rights”) Is Included Under the Definition of Patent Rights and Is Added to Appendix a of the License: [***]. Appendix a of the License Is Deleted in Its Entirety and Replaced With the Appendix a of This Second Amendment, Attached Hereto

from 10-K 16 pages First Amendment to Lease

from 8-K 25 pages Purchase and Sale Agreement by and Between Alexion Pharmaceuticals, Inc. (“Seller”) and Rubius Therapeutics, Inc

from S-1/A 15 pages Employment Agreement

from S-1/A 15 pages Employment Agreement

from S-1/A 17 pages Employment Agreement

from S-1/A 19 pages Employment Agreement

from S-1/A 11 pages Rubius Therapeutics, Inc. 2018 Employee Stock Purchase Plan